Form 4: Illumina CFO Ankur Dhingra Receives Stock Grants and Performance Shares

Ankur Dhingra, Illumina's CFO, received restricted stock units and performance shares, with vesting and payout contingent on continued service and company performance metrics.

Summary

• Ankur Dhingra, the SVP and Chief Financial Officer of Illumina, Inc., reported changes in beneficial ownership on March 5, 2025.
• Dhingra was granted 9,803 shares of common stock.
• He also received 11,437 performance shares tied to the company's three-year average operating margin for fiscal years 2025-2027, vesting on January 2, 2028.
• An additional 11,437 performance shares were granted, linked to Illumina's relative total shareholder return for the fiscal year ending January 2, 2028.
• The number of shares issued for both performance share grants will range from 0% to 250% of the specified amount, based on performance against pre-defined objectives.
• As a result of Illumina's spin out of Grail, Inc. on June 24, 2024, Dhingra's unvested RSUs were increased by 177 units.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, indicating confidence in the company's future performance. The performance-based awards suggest a positive outlook, but the actual value depends on future results.

Positives

• The grant of restricted stock units and performance shares aligns Dhingra's interests with the long-term success of Illumina.
• The performance-based vesting of shares incentivizes Dhingra to achieve specific financial and shareholder return targets.
• The adjustment of unvested RSUs due to the Grail spin-out ensures fair compensation for Dhingra.

Risks

• The actual number of performance shares received depends on Illumina's future financial performance and shareholder return, which are subject to market and operational risks.
• The vesting of restricted stock units is contingent on Dhingra's continued employment with Illumina.

Future Outlook

The number of performance shares ultimately received by Dhingra will depend on Illumina's financial performance and shareholder return over the next few years.

Industry Context

Stock grants and performance-based compensation are common practices in the biotechnology industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Companies like Thermo Fisher Scientific, Danaher, and Agilent Technologies also utilize stock options, restricted stock units, and performance shares as part of their executive compensation packages.
• The specific metrics used for performance-based awards (e.g., operating margin, total shareholder return) are typical for the industry and reflect key drivers of shareholder value.

Stakeholder Impact

• Shareholders: The stock grants and performance shares align executive compensation with shareholder value creation.
• Employees: The compensation structure can motivate employees by aligning their efforts with company performance.

Key Dates